Edition:
United Kingdom

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

2.17USD
19 Apr 2018
Change (% chg)

$0.04 (+1.88%)
Prev Close
$2.13
Open
$2.14
Day's High
$2.17
Day's Low
$2.11
Volume
16,933
Avg. Vol
22,635
52-wk High
$3.26
52-wk Low
$1.51

Select another date:

Mon, Feb 26 2018

BRIEF-Mei Pharma Inc says ‍On Feb 22, Board Voted To Increase Size Of Board By One Seat

* MEI PHARMA INC - ‍ON FEBRUARY 22, 2018, BOARD OF CO VOTED TO INCREASE SIZE OF BOARD BY ONE SEAT -SEC FILING​ Source text - (http://bit.ly/2EUshBn) Further company coverage:

BRIEF-MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study

* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER

BRIEF-MEI Pharma Q2 Loss Per Share $0.16

* ‍AS OF DECEMBER 31, 2017, HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS, WITH NO OUTSTANDING DEBT​

BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency

* HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

BRIEF-MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib

* MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB

BRIEF-Mei Pharma enters into at-market equity offering sales agreement

* On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​

Select another date: